Log In
BCIQ
Print this Print this
 

Anifrolumab (formerly MDX-1333, MEDI-546)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHuman mAb targeting type I interferon (IFN) receptor 1
Molecular Target Type I interferon (IFN) receptor 1
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationLupus
Indication DetailsTreat lupus nephritis; Treat systemic lupus erythematosus (SLE)
Regulatory Designation
PartnerAstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,400.0M

$2,400.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/07/2009

$2,400.0M

$2,400.0M

0

Get a free BioCentury trial today